Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$15,741,256
-$4,762,649 QoQ
Shares Held
875,487
0.0% QoQ
Ownership
1.80%
of shares outstanding
% of Portfolio
0.32%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 22%
Shared 0%
None 78%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ORBIMED ADVISORS LLC holds $2,871,604,021 across 72 Biotechnology names. URGN ranks #40 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EWTX |
Edgewise Therapeutics, Inc.
|
15,518,492 | $488,832,498 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
7,959,538 | $312,013,889 | |
| 3 | SION |
Sionna Therapeutics, Inc.
|
3,530,702 | $141,545,843 | |
| 4 | MBX |
MBX Biosciences, Inc.
|
3,637,887 | $108,590,926 | |
| 5 | CRVS |
Corvus Pharmaceuticals, Inc.
|
7,165,006 | $104,824,037 | |
| 6 | ARGX |
Argenx SE
|
136,900 | $99,971,225 | |
| 7 | CMPX |
Compass Therapeutics, Inc.
|
15,219,994 | $80,513,768 | |
| 8 | GPCR |
Structure Therapeutics Inc.
|
1,475,403 | $71,114,424 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15,741,256 | 875,487 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $20,503,905 | 875,487 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $13,745,550 | 689,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $6,554,080 | 478,400 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||